Aquestive Therapeutics (AQST) Projected to Post Earnings on Wednesday

Aquestive Therapeutics (NASDAQ:AQST) is expected to be issuing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $11.02 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The business had revenue of $13.82 million for the quarter, compared to the consensus estimate of $11.42 million. On average, analysts expect Aquestive Therapeutics to post ($0.50) EPS for the current fiscal year and ($0.50) EPS for the next fiscal year.

Aquestive Therapeutics Stock Up 2.5%

Shares of Aquestive Therapeutics stock opened at $4.07 on Wednesday. Aquestive Therapeutics has a 12-month low of $2.93 and a 12-month high of $7.05. The company has a 50-day moving average of $4.68 and a two-hundred day moving average of $4.21.

Insider Transactions at Aquestive Therapeutics

In other Aquestive Therapeutics news, CEO Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $4.22, for a total transaction of $105,500.00. Following the completion of the transaction, the chief executive officer owned 627,317 shares in the company, valued at approximately $2,647,277.74. The trade was a 3.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sherry Korczynski sold 8,750 shares of the company’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $5.22, for a total transaction of $45,675.00. Following the completion of the sale, the insider directly owned 235,689 shares in the company, valued at $1,230,296.58. This trade represents a 3.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 58,750 shares of company stock worth $271,675. 6.81% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on AQST. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Friday, October 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 price objective on shares of Aquestive Therapeutics in a report on Thursday, September 10th. Finally, Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.60.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.

Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis.